Diets · Metabolic & Cardiometabolic
LDL cholesterol is-a-cardiovascular-risk-factor-even-on a low-carb or carnivore diet
In plain terms: Is high LDL on a carnivore diet still a heart concern?
Strong support Diets 💰 Industry COI noted🔬 Includes disconfirming⚠️ Includes retracted (not counted)
RefutedContestedStrong support
consensus score 0.92
Yes — LDL/ApoB is causal for atherosclerosis by genetics and trials; there is no evidence carnivore-induced high LDL is exempt, so Baker's dismissal is not supported.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 0 contradict 2 tested null 1 mixed · 10 sources, 7 independent groups · 1 retracted, not counted
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sanchez-Quesada 2026 · Front Endocrinol | observational | supports | moderate | Cumulative lifetime LDL-C exposure (cohorts, FH, MR) causally drives CV risk regardless of when measured. |
| Budoff M, ... Norwitz NG, et al. (KETO Trial) 2024 · JACC Adv | observational | tested-null | low | KETO trial: lean-mass-hyper-responders on carbohydrate restriction develop very high LDL-C; framed by low-carb advocates as possibly benign, but plaque outcomes remained under study — does not exonerate high LDL. |
| Norwitz NG, Soto-Mota A, et al. 2022 · Front Endocrinol | n-of-1 | tested-null | low | Single LMHR case with LDL-C to 545 mg/dL and no CT-angiography plaque after ~2 years — an anecdotal n-of-1 offered against LDL concern; hypothesis-generating only, not evidence of safety. |
| Soto-Mota A, Norwitz NG, ... Budoff M 2025 · JACC Adv (RETRACTED 2026) | observational | contradicts | low | Keto lean-mass hyper-responders: baseline plaque predicted progression; authors argue ApoB did not — small, advocacy-linked, contested (Feldman-Norwitz network). ⚠️ RETRACTED — not counted |
| Kalra, Ray, Bajaj, Kushner, Wilcox, Dicklin, Kirkpatrick, Maki 2026 · J Clin Lipidol 2026;20(4):738-749 | meta-analysis | supports | high | Meta-analysis of 14 primary-prevention LDL-lowering outcomes trials: 'In CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated with a 30% RRR in 4-point MACE' (RR 0.70; 95% CI 0.67-0.74). This supports LDL-C as a modifiable cardiovascular risk factor in people without established disease; the paper's own wording is 'was associated with', and pooled drug trials are not a causal-inference design in the Mendelian-randomization sense, so the earlier 'confirming LDL-C as a causal ... risk factor' phrasing is dropped. The claim's discriminating modifier - 'even on a low-carb or carnivore diet' - is UNTESTED here: diet is not an exposure, stratifier or subgroup in this corpus of drug trials (same limitation recorded for s30073316 and s33186535). Abstract-only read; heavy author industry COI. |
| Sabatine, Wiviott, Im, Murphy, Giugliano 2018 · JAMA Cardiol. 2018 Sep 1;3(9):823-828 | meta-analysis | supports | high | Meta-analysis of trials whose populations already START at median LDL-C 1.8 mmol/L (70 mg/dL) or less: further lowering still cut major vascular events - statin subgroup RR 0.78 (95% CI 0.65-0.94, 1,922 events), 3 nonstatin add-on trials RR 0.79 (0.70-0.88; 50,627 patients, 9,570 events), combined RR 0.79 (0.71-0.87, P < .001) per 1 mmol/L, holding down to a median achieved 0.5 mmol/L (21 mg/dL) with no offsetting harms detected. Supports LDL causality with no evident threshold. SCOPE CAVEAT: no low-carb or carnivore population is studied here - diet is not an exposure, stratifier or subgroup anywhere in the paper, so the claim's dietary qualifier is untested by this source (as it is by its 11 siblings; routed as a claim-level question, not cut here). |
| Cooper ID, ... Norwitz NG, Soto-Mota A 2023 · Front Endocrinol | observational | mixed | low | Lipid Energy Model: in lean people carb-restriction raises LDL via lipid trafficking — explains the rise, does not prove it is benign. |
| Pirillo 2026 · Pharmacol Rev | observational | supports | high | Review synthesizing genetics, Mendelian randomization and trials: cumulative LDL-C exposure is causal for lifelong ASCVD risk and lowering it reduces events. |
| Wang 2022 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Each mmol/L LDL-C lowering cuts major CV events; Mendelian randomization shows lifetime LDL causally raises risk. |
| Kronenberg 2022 · Eur Heart J | observational | supports | moderate | EAS consensus (large genetic + epidemiologic data) states elevated ApoB-containing lipoproteins are causal for ASCVD and confer risk even at low LDL-C, reinforcing that high LDL/ApoB is a genuine concern. |
| Lincoff 2024 · J Am Coll Cardiol | RCT | supports | high | CLEAR Outcomes: bempedoic-acid LDL-C lowering (~21%) in statin-intolerant patients cut major adverse cardiovascular events ~13%, independent of statins, reinforcing LDL causality. |
| Gencer 2020 · Lancet | meta-analysis | supports | high | Supports the general core; silent on the dietary context. In 21 492 patients aged >=75 across 29 RCTs, 'LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61-0·89]; p=0·0019)', consistent across cardiovascular death, MI, stroke and revascularisation. Scope limit to record: every participant is in a DRUG-treatment outcome trial — no low-carb or carnivore exposure is studied — so this evidences LDL as a modifiable CV risk factor generally, not the claim's 'even on a low-carb or carnivore diet' modifier. (Abstract-grade.) |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.